Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Eosin Y (AC158)
Cat.#: ASSD-158
Specifications
Description Eosin Y is a xanthene dye that stains the cytoplasm and connective tissue. The compound is suitable for counterstaining tissue after nuclear staining. It is a component of the H&E stain (Hematoxylin and eosin stain) which is one of the most commonly utilised histological tissue stains. Size 1g Chemical Name 2′,4′,5′,7′-Tetrabromofluorescein Molecule Weight 691.85 Molecular formula C20H6Br4O5.2Na CAS Number 17372-87-1 PubChem identifier 11048 MDL Number MFCD00005040 Purity >90% Solubility Soluble in water (100 mM) Form Red solid Storage Store at 4° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-117 Annexin V-PE Apoptosis Staining / Detection Kit (AC117) 1 kit, 100 tests inquiry ASSD-185 Cyanine 3 Maleimide, Potassium Salt (AC185) 500 μg inquiry ASSD-144 Oxazole Yellow Iodide (AC144) 1 mg inquiry ASSD-212 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate N-succinimidyl ester (AC212) 25 mg inquiry ASSD-107 Modified Mayer's Hematoxylin (AC107) 125 mL, 250 mL, 2×250mL inquiry ASSD-120 Fluorescent adenosine antagonist [XAC] (AC120) 500 μg inquiry ASSD-135 JC-1 (AC135) 5 mg inquiry ASSD-102 DAPI (AC102) 10 mg, 50 mg inquiry ASSD-138 A3AR covalent antagonist (AC138) 50 μg inquiry ASSD-121 Fluorescent adenosine A3 antagonist [XAC] (AC121) 500 μg inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket